Synonym
Pratosartan; KD-3-671; KT-3-671; DA-727; KD-3671; KT-3671; KD3-671; KT3-671; DA727; KD3671; KT3671.
IUPAC/Chemical Name
2-Propyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-5,6,7,8-tetrahydrocycloheptaimidazol-4(3H)-one
InChi Key
KCTFTBCZZUBAKN-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H26N6O/c1-2-7-23-26-21-10-5-6-11-22(32)24(21)31(23)16-17-12-14-18(15-13-17)19-8-3-4-9-20(19)25-27-29-30-28-25/h3-4,8-9,12-15H,2,5-7,10-11,16H2,1H3,(H,27,28,29,30)
SMILES Code
O=C1CCCCC2=C1N(CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3)C(CCC)=N2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
426.52
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Tomillero A, Moral MA. Gateways to clinical trials. July-August 2008. Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):459-95. PubMed PMID: 18850047.
2: Li Y, Sato M, Yanagisawa Y, Mamada H, Fukushi A, Mikami K, Shirasaka Y, Tamai I. Effects of angiotensin II receptor blockers on renal handling of uric acid in rats. Drug Metab Pharmacokinet. 2008;23(4):263-70. PubMed PMID: 18762713.
3: Ogihara T, Saruta T, Shimamoto K, Matsuoka H, Rakugi H. Clinical efficacy of a new angiotensin II type 1 receptor blocker, pratosartan, in hypertensive patients. Hypertens Res. 2008 Feb;31(2):281-7. doi: 10.1291/hypres.31.281. PubMed PMID: 18360048.
4: Sato M, Iwanaga T, Mamada H, Ogihara T, Yabuuchi H, Maeda T, Tamai I. Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers. Pharm Res. 2008 Mar;25(3):639-46. Epub 2007 Aug 3. PubMed PMID: 17674156.
5: Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther. 2007 Jan;320(1):211-7. Epub 2006 Oct 16. PubMed PMID: 17043154.
6: Sonegawa M, Suzaka H, Tomiyama A, Tomiyama T. Synthesis and pharmacological activity of the metabolites of Pratosartan. Chem Pharm Bull (Tokyo). 2006 Jun;54(6):782-7. PubMed PMID: 16755044.
7: Sonegawa M, Yokota M, Tomiyama H, Tomiyama T. Regioselective alkylation of 2-alkyl-5,6,7,8-tetrahydro-3h-cycloheptimidazol-4-ones and 2-alkyl-3h-cycloheptimidazol-4-ones. Chem Pharm Bull (Tokyo). 2006 May;54(5):706-10. PubMed PMID: 16651773.
